Bacteriófagos: aspectos generales y aplicaciones clínicas
DOI:
https://doi.org/10.17533/udea.hm.335348Palabras clave:
bacteriófagos, control biológico, resistencia bacterianaResumen
En este artículo se recopila la información publicada disponible respecto a la terapia con bacteriófagos, para así brindar al lector un documento de referencia en español para su consulta el cual incluye la definición, estructura morfológica, ciclo de vida de estos organismos, historia, alternativa a la antibiótico-resistencia, clasificación de los fagos, mecanismos de acción, implicaciones terapéuticas, ventajas y desventajas de esta terapia, así como el estado actual de la terapia con fagos. También se describen algunos ejemplos de utilización de fagos como en el control biológico de plagas en plantas e infecciones en animales, así como otras áreas de uso de los bacteriófagos, y se revisan los mecanismos de resistencia a los fagos, además del futuro de la terapia con bacteriófagos y termina con unas reflexiones finales de la fago terapia.
Descargas
Citas
Collier L. Virología humana. 3a ed. Korea: McGraw-Hill Interamericana; 2008.
Dalmasso M, Hill C, Ross RP. Exploiting gut bac-teriophages for human health. Trends Microbiol. 2014;22:399-405.
Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc Natl Acad Sci. 2016;113(37):10400-5
.4. Avendaño LF, Ferrés M, Spencer M. Virología Clínica. Santiago de Chile: Mediterraneo; 2011.
Norkin LC. Virology molecular biology and pathogen-esis. Washington: AMS Press; 2010.
Sturino JM, Laenhammer KT. Engineered bacterio-phage-defence systems in bioprocessing. Nat Rev Mi-crobiol. 2006;4(5):395-4004.
Kutateladze M, Adamia. Phage therapy experience at the Eliava Institute. Medicine et Maladies Infectiouses. 2008;38:426-430.
Carlton RM. Phage therapy: past history and future prospects. Arch Immunol Ther Exp. 1999;47(5):267-74. 9. Ackermann HW. History of Virology: Bacteriophages. In: Encyclopedia of Virology. 3.a ed. Amsterdam: Else-vier; 2008. p. 442-50.
Citorik RJ, Mimee M, Lu TK. Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol. 2014;2:59-69.
Villalba AJ, Martos CM, García MJ. Bacteríofagos y la terapia fágica. [s. l.]: [20--]; 2012.
Ackermann HW. Frequency of morphological phage descriptions in the year. Br Rev Arch Virol. 2001;146:843-57.
Tortora, G, Funke B, Case C. Microbiology: An Intro-duction. San Francisco: Pearson Education; 2010.
McClean T. Bacteriophages as a New Drug. Bacterio-phages as a New Drug. [Internet]. [Consultado 2015 oct 20] Disponible en: http://healingseekers.com/wp-content/themes/healin.
Brüssow H. What is needed for phage therapy to become a reality in Western medicine? Virology. 2012;434:138-42.
Dini C. Aislamiento y caracterización molecular de bacteriófagos de bacterias enteropatógenas para bio-control de enfermedades transmitidas por alimentos (ETA). [Tesis Doctoral Ciencias Exactas]. Argentina: Uni-versidad Nacional de la Plata; 2011.
Kittler S, Wittmann J, Mengden L, Klein G, Rohde C, Lehnherr H. The use of bacteriophages as One-Health approach to reduce multidrug-resistant bacteria. Sus-tain Chem Pharm. 2016;5:80-83.
Subirats J, Sànchez-Melsió AM, Borrego C, Balcá-zar JL, Simonet P. Metagenomic analysis reveals that bacteriophages are reservoirs of antibiotic resistance genes. Int J Antimicrob Agents. 2016;48(2):163-7.
Klumpp J, Loessner M. New research on bacte-riophages and food safety. Adv Microb Food Saf. 2013;1:321-39.
Shivshetty N, Hosamani R, Ahmed L, Oli AK, San-nauallah S, Sharanbassappa S, et al. Experimental Protection of Diabetic Mice against Lethal P. aeru-ginosa Infection by Bacteriophage. Biomed Res Int. 2014;2014:ID 793242.
Cooper IR. A review of current methods using bacte-riophages in live animals, food and animal products in-tended for human consumption. J Microbiol Methods. 2016;130:38-47.
Marvin DA. Symmons MF, Straus SK. Structure and assembly of filamentous bacteriophages. Prog Biophys Mol Biol. 2014;114:80-122.
Ghang S, Shimamura I, Fukunaga M, Mori K, Nakai T. Isolation of bacteriophages specific to fish patho-gen, Pseudeomonas plecoglossicida, as a candi-date for disease control. Appl an Environ Microbiol. 2006;66(4):1416-22.
Ronda C, Vázquez M, López R. Los bacteriófagos como herramienta para combatir infecciones en Acui-cultura. Rev Aquat. 2003;18:3-10.
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, et al. Use of bacteriofage in the treatment of experimental animal bacteremia from imipenen-resistant Pseudomonas ae-ruginosa. Int J Mol Med. 2006;17:3009-17.
Capparelli R, Parlato M, Borriello G, Salvatore P ID. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51:2765-73.
García-Suarez P, Martínez-Fernández B, Rodríguez-González A. Nuevas alternativas en el tratamiento de la mamitis en el ganado vacuno. Tecnol Agropecu. 2008;5:55-8.
Goldman G, Starosvetsky J, Armon R. Inhibition of biofilm formation on UF membrane by use of specific bacteriophages. J Memb Sci. 2009;342:145-52.
Janež N Loc-Carrillo C. Use of phages to control Cam-pylobacter spp. J Microbiol Methods. J Microbiol Meth-ods. 2013;95(1):68-75.
Akhtar M, Viazis S, Diez-González F. Isolation, iden-tification and characterization of lytic, wide host range bacteriophages from waste effluents against Salmo-nella enterica serovars. Food Control. 2014;38:67-74.
Fujiwara A, Fujisawa M, Hamasaki R, Kawasaki T, Fu-jie M, Yamada T. Biocontrol of Ralstonia solanacearum by Treatment with Lytic Bacteriophages. Appl Env Mi-crobiol. 2011;77(12):4155-2.
Lee SH, Hosseindoust AR, Kim JS, Choi YH, Lee JH, Kwon IK, et al. Bacteriophages as a promising anti-pathogenic option in creep-feed for suckling piglets: Targeted to control Clostridium spp. and coliforms fae-cal shedding. Livest Sci. 2016;191:161-4.
Duc Hoang M, Son Hoang M, Ken-Ichi H, Miyamo-to T. Isolation and bio-control of Extended Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli con-tamination in raw chicken meat by using lytic bacterio-phages. LWT-Food Sci Technol. 2016;71:339-346.
Petty NK, Evans TJ, Fineran PC, Salmond GPC. Bio-technological exploitation of bacteriophage research. Trends Biotechnol. 2007;25:7-15.
Sillankorva SM, Oliveira H, Azeredo J. Bacteriophag-es and Their Role in Food Safety. Int J Microbiol. 2012;1-13. 36. Larco J, Egas P, Villavicencio F, Ushiña L, Trueba G. Bacteriófago como alternativa a los antimicrobianos. [Internet] [Consultado 2015 oct 20]. Disponible en: http://bacteriasactuaciencia.blogspot.com/
Thiel K. Old dogma, new tricks —21st Century phage therapy. Nat Biotechnol. 2004;22:31-6.
Labrie SJ, Samson JE, Moineau S. Mechanisms, Bac-teriophage resistance. Nat Rev Microbiol. 2010;8:317-27. 39. Sanders ME. Phage resistance in lactic acid bacteria. Biochimie. 1988;70(3):411-22.
Hechos Microbiol. 2015;6(1-2):36-51.
Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010;70:217-48.
Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic en-zyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun. 2003;71:6199-2004.
Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci. 2001; 98:4107-12.
Yoong P, Schuch R, Nelson D, Fischetti VA. Identifica-tion of a Broadly Active Phage Lytic Enzyme with Le-thal Activity against Antibiotic-Resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol. 2004; 186(14):4808-12.
Lu TK, Koeris MS. The next generation of bacterio-phage therapy. Curr Opin Microbiol. 2011; 14(5):524-31.